title: Reduced production of IFN-γ and LT-α is associated with successful prednisone therapy in patients with acquired hemophilia A: a pilot study.
abstract: Glucocorticoids (GC) are a standard treatment for acquired hemophilia A (AH). Although the optimal treatment regimen and duration of GC's is unknown, measurement of sub-clinical immune responses may help direct therapeutic decision making. To study the helpfulness of this approach, three male patients diagnosed with AH were treated with prednisone. The therapy resulted in inhibitor elimination in two out of the three individuals. During the treatment, peripheral mononuclear cells were isolated at different time points and stimulated in vitro. The expression of IFN-γ and LT-α were monitored at both the protein and the mRNA levels. The amount of IFN-γ and LT-α were markedly reduced by the time of inhibitor disappearance in the patients responding to GC therapy but remained high in the non-responder until cyclophosphamide was added. This study suggests that the secretion level of IFN-γ and/or LT-α could be a predictive marker of prednisone responsiveness.
authors.affiliation: Tulane University Health Sciences Center, Tulane School of Medicine, Section of Hematology/Oncology, Louisiana Comprehensive Hemophilia Care Center, New Orleans, LA 70112-2699, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Kruse-Jarres
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Leissinger
authors.forename: Frédéric
authors.initials: F
authors.lastname: Ganapamo
mesh_terms: D000368:Aged; D015415:Biomarkers; D003520:Cyclophosphamide / Q000627:therapeutic use; D006467:Hemophilia A / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007371:Interferon-gamma / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D008233:Lymphotoxin-alpha / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008233:Lymphotoxin-alpha; D012333:RNA, Messenger; D007371:Interferon-gamma; D003520:Cyclophosphamide; D011241:Prednisone